BE2013C036I2 - - Google Patents

Download PDF

Info

Publication number
BE2013C036I2
BE2013C036I2 BE2013C036C BE2013C036C BE2013C036I2 BE 2013C036 I2 BE2013C036 I2 BE 2013C036I2 BE 2013C036 C BE2013C036 C BE 2013C036C BE 2013C036 C BE2013C036 C BE 2013C036C BE 2013C036 I2 BE2013C036 I2 BE 2013C036I2
Authority
BE
Belgium
Application number
BE2013C036C
Other languages
French (fr)
Original Assignee
Sanofi Mature Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Mature Ip filed Critical Sanofi Mature Ip
Publication of BE2013C036I2 publication Critical patent/BE2013C036I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
BE2013C036C 2003-09-19 2013-06-13 BE2013C036I2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0311016A FR2859996B1 (fr) 2003-09-19 2003-09-19 Solvat acetonique du dimethoxy docetaxel et son procede de preparation
PCT/FR2004/002344 WO2005028462A1 (fr) 2003-09-19 2004-09-16 Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Publications (1)

Publication Number Publication Date
BE2013C036I2 true BE2013C036I2 (ja) 2023-12-14

Family

ID=34224354

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C036C BE2013C036I2 (ja) 2003-09-19 2013-06-13

Country Status (38)

Country Link
US (1) US7241907B2 (ja)
EP (1) EP1667986B1 (ja)
JP (1) JP5010279B2 (ja)
KR (1) KR101123588B1 (ja)
CN (1) CN100429207C (ja)
AR (1) AR045667A1 (ja)
AU (1) AU2004274212B2 (ja)
BE (1) BE2013C036I2 (ja)
BR (1) BRPI0414492A8 (ja)
CA (1) CA2539309A1 (ja)
CR (1) CR8292A (ja)
CY (2) CY1114575T1 (ja)
DK (1) DK1667986T3 (ja)
ES (1) ES2403149T4 (ja)
FR (1) FR2859996B1 (ja)
HK (1) HK1093340A1 (ja)
HR (1) HRP20130322T1 (ja)
HU (1) HUS1300025I1 (ja)
IL (1) IL174240A (ja)
LU (1) LU92172I2 (ja)
MA (1) MA28045A1 (ja)
ME (2) MEP11708A (ja)
MX (1) MXPA06002639A (ja)
MY (1) MY136668A (ja)
NO (2) NO335997B1 (ja)
NZ (1) NZ545835A (ja)
PA (1) PA8612401A1 (ja)
PE (1) PE20050870A1 (ja)
PL (1) PL1667986T3 (ja)
PT (1) PT1667986E (ja)
RS (2) RS54614B1 (ja)
RU (1) RU2342373C2 (ja)
SI (1) SI1667986T1 (ja)
TN (1) TNSN06086A1 (ja)
TW (1) TWI382022B (ja)
UA (1) UA87115C2 (ja)
WO (1) WO2005028462A1 (ja)
ZA (1) ZA200602255B (ja)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080100264A (ko) * 2006-03-21 2008-11-14 닥터 레디스 레보러터리즈 리미티드 도세탁셀의 다형체와 그 제조방법
US7855591B2 (en) * 2006-06-07 2010-12-21 Atmel Corporation Method and system for providing a charge pump very low voltage applications
US7652522B2 (en) * 2006-09-05 2010-01-26 Atmel Corporation High efficiency low cost bi-directional charge pump circuit for very low voltage applications
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス, インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
AU2013205442B2 (en) * 2008-01-17 2016-05-12 Aventis Pharma S.A. Crystalline forms of dimethoxy docetaxel and methods for preparing same
FR2926551A1 (fr) * 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
CA2732508C (en) 2008-08-11 2016-03-15 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
FR2945211A1 (fr) * 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
AU2015200149B2 (en) * 2009-10-29 2016-12-01 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
DK2493466T3 (da) * 2009-10-29 2021-04-26 Sanofi Mature Ip Hidtil ukendt antitumoral anvendelse af cabazitaxel
CA2708489A1 (en) * 2009-10-29 2011-04-29 Aventis Pharma S.A. Use of cabazitaxel and a prednisone or a prednisolone in the treatment of prostate cancer
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
JP2014514306A (ja) * 2011-04-12 2014-06-19 プラス・ケミカルス・エスアー 固体形態のカバジタキセル及びその製造方法
WO2013024495A1 (en) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Pharmaceutical formulations of cabazitaxel
TWI526437B (zh) 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
US8722900B2 (en) 2011-10-31 2014-05-13 Scinopharm Taiwan, Ltd. Process for cabazitaxel, and intermediates thereof
CN103874692A (zh) 2011-11-01 2014-06-18 费森尤斯卡比肿瘤学有限公司 卡巴他赛的无定形形式和用于其制备的方法
WO2013080217A2 (en) 2011-11-28 2013-06-06 Fresenius Kabi Oncology Ltd. Crystalline forms of carbazitaxel and process for preparation thereof
EP2791122B1 (en) 2011-12-13 2019-01-23 Aventis Pharma S.A. Crystalline form of cabazitaxel and process for preparing the same
WO2013111157A1 (en) * 2012-01-03 2013-08-01 Shilpa Medicare Limited Process for preparing amorphous cabazitaxel
BR112014019675A2 (pt) * 2012-02-10 2017-07-11 Aventis Pharma Sa usos pediátricos de cabazitaxel
CN104220431A (zh) 2012-03-08 2014-12-17 伊瓦克斯国际有限责任公司 卡巴他赛的固态形式及其制备方法
CN102675257B (zh) * 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
EP2880021A4 (en) 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd AMORPHIC CABACITAXEL
WO2014028704A1 (en) 2012-08-15 2014-02-20 Yung Shin Pharm. Ind. Co., Ltd. Stable pharmaceutical formulation of cabazitaxel
CN103664836B (zh) * 2012-09-20 2016-04-20 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
EP2743264A1 (en) 2012-12-13 2014-06-18 INDENA S.p.A. New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
CN103910696B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛异丙醚合物及其结晶
CN103910698B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛丙酮合物及其结晶
EP2777691A1 (en) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
CN104277014A (zh) * 2013-07-04 2015-01-14 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
WO2015000165A1 (zh) * 2013-07-04 2015-01-08 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
EP2865675A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
EP2865674A1 (en) 2013-10-23 2015-04-29 INDENA S.p.A. Crystalline solvate forms of Cabazitaxel
CN103601704B (zh) * 2013-11-22 2015-05-06 石家庄智恒医药科技有限公司 无定形卡巴他赛的制备
EP3247350B1 (en) 2015-01-12 2021-12-22 Emcure Pharmaceuticals Limited Liquid formulation of cabazitaxel
US10555926B2 (en) * 2015-02-17 2020-02-11 Erasmus University Medical Center Rotterdam Use of cabazitaxel in the treatment of prostate cancer
EP3093014A1 (en) 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel and its use for treating cancer
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
BR122021026889A8 (pt) 2016-11-29 2022-11-22 Censa Pharmaceuticals Inc Formas cristalinas de base livre de sepiapterina e de sais dos mesmos, seu método de preparação, composições que as compreendem, uso dos mesmos e método de preparação de uma formulação líquida
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
JP2020532535A (ja) 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277382A1 (en) 2018-05-30 2021-01-21 Ptc Therapeutics Mp, Inc. Methods for increasing sepiapterin plasma exposure
WO2020249507A1 (en) 2019-06-11 2020-12-17 Indena S.P.A. Anhydrous crystalline form of cabazitaxel, a process for its preparation and pharmaceutical compositions containing it
EP3797834A1 (en) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent
EP3808345A1 (en) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
EP0982027A1 (en) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Taxoid derivatives for treating abnormal cell proliferation of the brain
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) * 1999-01-07 1999-10-19 508037 (Nb) Inc. Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
MXPA01011046A (es) * 1999-05-17 2002-07-22 Squibb Bristol Myers Co Novedosas condiciones de reaccion para la escicion de teres de sililo en la preparacion de paclitaxel (taxol, marca registrada) y analogos de paclitaxel.
ES2299612T3 (es) * 2001-11-29 2008-06-01 Daiichi Sankyo Company, Limited Cristales de un derivado de taxano y procedimiento de obtencion.

Also Published As

Publication number Publication date
LU92172I2 (fr) 2013-05-21
MEP11708A (en) 2010-06-10
RU2006113122A (ru) 2006-08-27
ES2403149T3 (es) 2013-05-14
FR2859996A1 (fr) 2005-03-25
RU2342373C2 (ru) 2008-12-27
CY1114575T1 (el) 2016-10-05
ES2403149T4 (es) 2013-06-24
NO335997B1 (no) 2015-04-20
AU2004274212B2 (en) 2010-03-04
BRPI0414492A (pt) 2006-11-14
FR2859996B1 (fr) 2006-02-03
HUS1300025I1 (hu) 2016-08-29
JP5010279B2 (ja) 2012-08-29
HRP20130322T1 (en) 2013-07-31
TW200524891A (en) 2005-08-01
PT1667986E (pt) 2013-04-24
HK1093340A1 (en) 2007-03-02
KR101123588B1 (ko) 2012-03-22
EP1667986A1 (fr) 2006-06-14
US7241907B2 (en) 2007-07-10
RS54614B1 (en) 2016-08-31
CN100429207C (zh) 2008-10-29
CY2013016I2 (el) 2018-01-10
CN1849311A (zh) 2006-10-18
NO2015013I2 (no) 2015-04-22
IL174240A (en) 2010-12-30
PL1667986T3 (pl) 2013-06-28
EP1667986B1 (fr) 2013-01-16
US20050065138A1 (en) 2005-03-24
MA28045A1 (fr) 2006-07-03
MXPA06002639A (es) 2006-06-05
PA8612401A1 (es) 2005-08-04
NZ545835A (en) 2009-10-30
NO2015013I1 (no) 2015-05-04
AU2004274212A1 (en) 2005-03-31
ZA200602255B (en) 2007-07-25
CA2539309A1 (fr) 2005-03-31
DK1667986T3 (da) 2013-05-06
CY2013016I1 (el) 2018-01-10
PE20050870A1 (es) 2005-11-21
ME00054B (me) 2011-02-10
BRPI0414492A8 (pt) 2019-01-15
NO20061714L (no) 2006-04-19
TNSN06086A1 (en) 2007-10-03
IL174240A0 (en) 2006-08-01
MY136668A (en) 2008-11-28
RS20060189A (en) 2008-06-05
AR045667A1 (es) 2005-11-02
TWI382022B (zh) 2013-01-11
UA87115C2 (ru) 2009-06-25
CR8292A (es) 2008-10-15
LU92172I9 (ja) 2019-01-03
JP2007505866A (ja) 2007-03-15
SI1667986T1 (sl) 2013-05-31
WO2005028462A1 (fr) 2005-03-31
KR20060072147A (ko) 2006-06-27

Similar Documents

Publication Publication Date Title
FR14C0034I1 (ja)
BE2013C075I2 (ja)
BE2013C070I2 (ja)
BE2013C067I2 (ja)
BE2013C038I2 (ja)
LU92172I9 (ja)
BE2011C030I2 (ja)
JP2003264750A5 (ja)
JP2003255117A5 (ja)
BE2012C053I2 (ja)
JP2003271569A5 (ja)
AU2002254171A1 (ja)
AU2002353888A1 (ja)
AU2002340206A1 (ja)
AU2002322913A1 (ja)
AU2002318342A1 (ja)
AU2002316511A1 (ja)
AU2002316235A1 (ja)
AU2002311957A1 (ja)
AU2002310561A1 (ja)
AU2002256398A1 (ja)
AU2002255066A1 (ja)
AU2002327042A1 (ja)
AU2002253451A1 (ja)
AU2002249912A1 (ja)